PALMIERI, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 21.972
AS - Asia 10.479
SA - Sud America 6.462
EU - Europa 5.607
Continente sconosciuto - Info sul continente non disponibili 573
AF - Africa 403
OC - Oceania 40
Totale 45.536
Nazione #
US - Stati Uniti d'America 21.368
BR - Brasile 5.742
SG - Singapore 4.980
CN - Cina 2.304
IT - Italia 1.395
UA - Ucraina 1.329
HK - Hong Kong 971
VN - Vietnam 831
DE - Germania 622
FR - Francia 606
SE - Svezia 424
FI - Finlandia 308
GB - Regno Unito 247
CA - Canada 238
AR - Argentina 208
TR - Turchia 183
MX - Messico 157
BD - Bangladesh 152
IN - India 148
EC - Ecuador 137
IQ - Iraq 134
RU - Federazione Russa 125
ZA - Sudafrica 109
VE - Venezuela 99
MA - Marocco 93
CO - Colombia 87
JP - Giappone 83
UZ - Uzbekistan 79
PL - Polonia 78
PK - Pakistan 69
KR - Corea 68
NL - Olanda 68
AT - Austria 66
ES - Italia 58
JO - Giordania 50
PY - Paraguay 50
CL - Cile 49
KE - Kenya 49
ID - Indonesia 45
TN - Tunisia 45
AZ - Azerbaigian 42
BE - Belgio 42
AE - Emirati Arabi Uniti 39
RO - Romania 39
AU - Australia 36
UY - Uruguay 36
LT - Lituania 33
NP - Nepal 31
HN - Honduras 30
PE - Perù 30
AL - Albania 27
EU - Europa 27
JM - Giamaica 27
KZ - Kazakistan 27
OM - Oman 25
CR - Costa Rica 24
DZ - Algeria 24
CZ - Repubblica Ceca 23
GT - Guatemala 23
LB - Libano 22
EG - Egitto 21
BO - Bolivia 20
SA - Arabia Saudita 20
SV - El Salvador 20
KG - Kirghizistan 19
IL - Israele 18
DO - Repubblica Dominicana 17
PH - Filippine 17
IR - Iran 16
RS - Serbia 16
TT - Trinidad e Tobago 16
BH - Bahrain 15
SN - Senegal 15
CH - Svizzera 14
NI - Nicaragua 14
PA - Panama 13
SY - Repubblica araba siriana 13
BY - Bielorussia 11
CI - Costa d'Avorio 11
GE - Georgia 11
IE - Irlanda 11
PS - Palestinian Territory 11
BG - Bulgaria 10
PR - Porto Rico 10
AM - Armenia 9
MY - Malesia 9
BA - Bosnia-Erzegovina 8
XK - ???statistics.table.value.countryCode.XK??? 8
ET - Etiopia 7
MN - Mongolia 7
PT - Portogallo 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GR - Grecia 6
HU - Ungheria 6
KW - Kuwait 6
NG - Nigeria 6
AO - Angola 5
BN - Brunei Darussalam 5
GP - Guadalupe 5
LK - Sri Lanka 5
Totale 44.925
Città #
Dallas 6.137
Singapore 2.733
Chandler 2.350
San Jose 1.830
Ashburn 1.287
Council Bluffs 975
Hong Kong 957
Princeton 769
Jacksonville 669
Santa Clara 648
Columbus 507
Beijing 438
São Paulo 394
Lauterbourg 373
Ho Chi Minh City 306
Wilmington 289
Dearborn 276
Milan 276
Nanjing 262
Shanghai 252
Hanoi 195
Los Angeles 188
New York 179
Belo Horizonte 172
Rio de Janeiro 158
Ann Arbor 151
Helsinki 141
Boardman 125
Brasília 115
Sassari 115
Nanchang 112
Orem 89
Porto Alegre 82
Curitiba 81
Rome 81
Campinas 80
Frankfurt am Main 80
Tokyo 80
Miano 74
The Dalles 74
Tianjin 72
Seoul 67
Tashkent 67
San Francisco 66
Nuremberg 65
Warsaw 63
Shenyang 61
Norwalk 60
Atlanta 58
Chicago 58
Brooklyn 56
Changsha 55
Montreal 55
Guarulhos 54
Johannesburg 54
Hebei 53
Toronto 53
Baghdad 52
Jiaxing 51
Amman 49
Da Nang 48
Buffalo 47
Goiânia 47
Osasco 45
Cagliari 44
Phoenix 44
Mexico City 43
Nairobi 43
Chennai 42
Guayaquil 42
Munich 42
Salvador 42
Ribeirão Preto 41
Santo André 40
Brussels 39
Dhaka 39
Istanbul 39
Fortaleza 38
Houston 36
Manaus 36
Mountain View 36
Quito 36
Stockholm 36
Woodbridge 36
Falls Church 35
Haiphong 35
London 35
Vienna 35
Amsterdam 34
Betim 34
Baku 33
Caxias do Sul 33
Denver 33
Joinville 33
Sorocaba 33
São Bernardo do Campo 33
Ankara 32
North Bergen 32
Recife 32
Campo Grande 31
Totale 26.783
Nome #
Clinical, Histopathological, Dermoscopic Features, and BRAF, NRAS, and Cell Cycle Genes’ Mutation Status in Cutaneous Melanoma 1.182
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 362
KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research 327
Allelic Gains And Losses At 10q25-Q26 In Malignancies Of The Uterine Corpus: Demonstration Of Two Distinctive Genetic Alterations 291
EGFR mutation detection in Whole Slide Images of non-small cell lung cancers using a two-stage deep transfer learning approach 279
Aspetti epidemiologici dei tumori maligni dell’ovaio nel Nord Sardegna nel periodo 1992-2001 261
Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations 229
Analysis of fanconi anemia genes in colorectal cancer 219
A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population 209
A Founder Mutation In Sardinian Breast Cancer Families Detected By Identity-By-Descent Method 208
Analysis of the mapk-erk gene pathway in primary and metastatic melanoma cell lines 205
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas 202
KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors 201
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases 201
A novel candidate gene in human endometrial cancer at chromosome 10q26 192
CASC2a gene is down-regulated in endometrial cancer 192
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 190
Breast cancer incidence and mortality in North Sardinia in the period 1992 - 2010 189
Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients 188
Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature 187
Long non-coding RNA CASC2 in human cancer 185
Genome-wide association study of susceptibility loci for breast cancer in Sardinian population 185
Epidemiology of thyroid cancer in an area of epidemic thyroid goiter 185
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study 179
A Diagnostic of Acquired Hemophilia Following PD1/PDL1 Inhibitors in Advanced Melanoma: The Experience of Two Patients and a Literature Review 176
Breast Nodular Fasciitis: A Comprehensive Review 176
Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy? 175
Phenotype characterization of human melanoma cells resistant to dabrafenib 172
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1,440 Sardinian patients with lung adenocarcinoma. 171
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 167
Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach 164
Disease progression and overall survival in sardinian patients with colorectal cancer according to the kras mutational status 161
Microsatellite analysis at 10q25-q26 in Sardinian patients with sporadic endometrial carcinoma - Identification of specific patterns of genetic alteration 160
Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series with Next-Generation Sequencing Mutation Analysis 158
Breast cancer incidence and mortality in North Sardinia in the period 1992–2010 158
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study 156
Genetic alterations in main candidate genes during melanoma progression 156
Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective 153
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study 153
Colorectal cancer epidemiology in an area with a spontaneous screening program 152
Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy 152
Presence of Jaagsiekte sheep retrovirus in tissue sections from human bronchioloalveolar carcinoma depends on patients' geographical origin 152
Genetic Instability Markers in Cancer 150
Repurposing anticancer drugs for the treatment of idiopathic pulmonary fibrosis and antifibrotic drugs for the treatment of cancer: state of the art 150
Fanconi genes may contribute to melanoma pathogenesis 150
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma 149
Fanconi genes are altered in subsets of patients with sporadic colorectal carcinoma 148
BRAF mutations and dysregulation of the MAP kinase pathway associated to sinonasal mucosal melanomas 148
Adjuvant therapy of cutaneous melanoma 148
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 146
X-inactivation patch size in human female tissue confounds the assessment of tumor clonality 145
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy 145
Cytogenetic assessment of the involvement of a new locus at 9p21 in malignant melanoma 144
Mutation analysis of mucosal and cutaneous melanomas during progression 143
Antitumoral effect of vanadium compounds in malignant melanoma cell lines 142
Adjuvant treatment of malignant melanoma: where are we? 142
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 142
Head and neck cancer epidemiology in North Sardinia, Italy. 140
Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer 140
Molecular classification of patients with malignant melanoma for new therapeutic strategies 139
Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report 139
Primary melanoma of the lung: A systematic review 139
KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma 139
2,2’-dihydroxy-3,3’-dimethoxy-5,5’-dimethyl-6,6’-dibromo-1,1’-biphenyl: preparation, resolution, structure and biological activity 137
Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay 136
Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells 135
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer 135
Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6 134
Uterine perivascular epithelioid cell neoplasms (PEComas): Report of two cases and literature review 132
Epidemiological aspects of ovarian malignancies in North Sardinia in the period 1992-2001 131
Anticancer activity of two novel hydroxylated biphenyl compounds toward malignant melanoma cells 131
Actin-binding protein (ABP-280) filamin gene maps telomeric to the color vision locus (R/GCP) and centromeric to G6PD in Xq28. 131
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 131
Mutational analysis of candidate genes in families with malignant melanoma (MM): assessment of the role of the CDKN2A gene in MM predispositions 130
A Role ofBRCA1andBRCA2germline mutations in breast cancer susceptibility within Sardinian population 130
Antiproliferative activity of vanadium compounds: Effects on the major malignant melanoma molecular pathways 130
Microsatellite analysis at 10q25-q26 in Sardinian patients with sporadic endometrial carcinoma 129
The effect of COVID-19 emergency in the management of melanoma in Italy 129
BRCA1 and BRCA2 mutation analysis in breast cancer families from Sardinia 128
Microsatellite and fish analysis in endometrial cancer: Assessment of specific patterns of genetic and cytogenetic alterations with their clinical correlations 128
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: report of two cases with molecular analysis 128
Human gene mutations gene symbol: BRCA2 small insertion in breast cancer 128
Primary dermal melanoma in a patient with a history of multiple malignancies: a case report with molecular characterization 127
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer 127
Germline mutations in candidate genes among patients with cutaneous melanoma from Sardinia 126
Immunohistochemistry and biomolecular investigation for the evidence of JSRV-like retrovirus in human bronchiolo-alveolar carcinomas 126
3-year treatment with recombinant interferon- as adjuvant therapy of cutaneous malignant melanoma. 125
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy 125
Screening for founder mutations in BRCA1/2 tumor susceptibility genes among breast cancer families from North Sardinia 125
Indagini immunoistochimiche e biomolecolari per l’evidenziazione di retrovirus jsrv-correlati, in carcinomi bronchiolo-alveolari dell’uomo 125
Molecular alterations in key-regulator genes among patients with T4 breast carcinoma 124
Pancreatic cancer burden in North Sardinia, Italy 124
1.5-Mb YAC contig in Xq28 formatted with sequence-tagged sites and including a region unstable in the clones 124
Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases 123
X-inactivation patch size in human female tissue confounds the assessment of tumor clonality 123
Identification of different patterns of genetic alteration (a new minimal LOH region at chromosome 10q25-26 and genomic instability) in Sardinian patients with sporadic endometrial cancer and correlation with clinicopathological parameters 123
Assessment of the role of Fanconi Anemia (FA) genes in colorectal cancer: A new pathogenetic pathway? 122
Enhanced anti-tumor activity of a newcurcumin-related compound against melanoma and neuroblastoma cells 122
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival 122
Long Noncoding RNAs in Non-Small Cell Lung Cancer: State of the Art 122
Totale 16.916
Categoria #
all - tutte 199.765
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.765


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.426 0 0 0 28 21 35 81 129 144 130 171 687
2022/20234.418 431 204 76 818 370 874 2 493 803 36 187 124
2023/20241.088 260 119 29 36 125 81 26 109 3 19 93 188
2024/202511.568 93 83 657 213 405 510 489 2.503 4.350 1.556 427 282
2025/202616.720 465 5.038 2.153 2.074 1.574 931 2.281 473 690 605 289 147
2026/20275.448 338 1.175 1.718 2.217 0 0 0 0 0 0 0 0
Totale 45.536